Study on the effect of rosuvastatin treatment on the prevention of thrombosis in patients with previous thrombosis - Du Lac
Study identifier:D3560L00093
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A randomised, double-blind, placebo-controlled, event driven, phase III study of rosuvastatin 20 mg once daily in the long term prevention of recurrent venous thromboembolism in patients with deep vein thrombosis or pulmonary embolism
Medical condition
Venous thrombosis, pulmonary embolism
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin (AZD4522), Placebo
Sex
All
Actual Enrollment
3000
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Feb 2011
Estimated Primary Completion Date: 01 Mar 2013
Estimated Study Completion Date: 01 Mar 2013
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Oral Treatment | Drug: Rosuvastatin (AZD4522) Oral dose (od) 20 mg Other Name: Crestor |
| Placebo Comparator: 2 Oral treatment | Drug: Placebo Oral dose (od) |
Contacts
Investigators
Principal Investigator
H. R. Büller
Academic Medical Centre
